Previous research by Ambrogio et al. (46) highlighted that “KRAS” dimerization enhances the survival of both human and murine KRAS mutant LUAD tumor cells possessing wild-type KRAS, explaining the observed resistance to MEK inhibition. The gene discussed is KRAS; the disease is neoplasm.